Premium
Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix
Author(s) -
Thompson Stephen,
Delaney Geoff,
Gabriel Gabriel Sam,
Jacob Susannah,
Das Prabir,
Barton Michael
Publication year - 2006
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22337
Subject(s) - medicine , brachytherapy , carcinoma , cervix , cervical carcinoma , cervical cancer , surgery , medical physics , radiation therapy , cancer
BACKGROUND. Brachytherapy (BT) is an integral part of cervical carcinoma treatment. There have been no attempts to estimate the optimal proportion of new cervical carcinoma cases that should be treated with BT, that is, the optimal rate of brachytherapy utilization (BTU). METHODS. Evidence‐based guidelines and primary evidence were used to construct a BTU tree for carcinoma of the uterine cervix. Searches were performed of the epidemiological literature to ascertain the proportion of patients who fulfilled criteria for BT. The robustness of the model was tested by sensitivity analyses and by peer review. A patterns of care study of BT in New South Wales for 2003 was conducted, and actual BTU for cervical carcinoma determined. The differences between optimal and actual rates of BTU were assessed. RESULTS. The optimal cervical carcinoma BTU was 49% (range, 42% to 50%). In New South Wales in 2003, actual BTU was only 30% of 256 cervical carcinoma patients. The major discrepancy was for FIGO stage IB‐IIA disease, where there was an underutilization of BT, estimated to be 15% actual use compared with 47% optimal use. In Surveillence, Epidemiology, and End Results (SEER) areas, there was underutilization for stage IB‐IIA (22% actual BTU versus 47% optimal BTU) and for stage IIB‐IVA (54% actual BTU versus 100% optimal BTU). CONCLUSIONS. BT for cervical carcinoma is underutilized in New South Wales and in SEER areas. The authors' model of optimal BTU can be used as a quality assurance tool to provide an evidence‐based benchmark against which actual patterns of practice can be measured. The model can also be used to help determine adequacy of BT resource allocation. Cancer 2006. © 2006 American Cancer Society.